[go: up one dir, main page]

NO20080991L - Bazedoksifen acetat formuleringer - Google Patents

Bazedoksifen acetat formuleringer

Info

Publication number
NO20080991L
NO20080991L NO20080991A NO20080991A NO20080991L NO 20080991 L NO20080991 L NO 20080991L NO 20080991 A NO20080991 A NO 20080991A NO 20080991 A NO20080991 A NO 20080991A NO 20080991 L NO20080991 L NO 20080991L
Authority
NO
Norway
Prior art keywords
bazedoxifene acetate
acetate formulations
formulations
bazedoxifene
compositions
Prior art date
Application number
NO20080991A
Other languages
English (en)
Inventor
Syed Muzafar Shah
Kadum Abdul Nabi Ali
Christopher Richard Diorio
Eric C Ehrnsperger
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37772333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20080991(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20080991L publication Critical patent/NO20080991L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

Foreliggende oppfinnelse omhandler formuleringer av bazedoksifenacetat som har redusert polymorf omforming, sammensetninger som inneholder disse, preparater derav og anvendelser derav.
NO20080991A 2005-08-24 2008-02-27 Bazedoksifen acetat formuleringer NO20080991L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71076105P 2005-08-24 2005-08-24
PCT/US2006/032935 WO2007024961A2 (en) 2005-08-24 2006-08-23 Bazedoxifene acetate formulations and manufacturing process thereof

Publications (1)

Publication Number Publication Date
NO20080991L true NO20080991L (no) 2008-05-15

Family

ID=37772333

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080991A NO20080991L (no) 2005-08-24 2008-02-27 Bazedoksifen acetat formuleringer

Country Status (21)

Country Link
US (1) US7771744B2 (no)
EP (1) EP1919456A2 (no)
JP (2) JP2009506053A (no)
KR (2) KR101584674B1 (no)
CN (1) CN101304731B (no)
AR (1) AR056471A1 (no)
AU (1) AU2006283121A1 (no)
BR (1) BRPI0615341A2 (no)
CA (1) CA2620174A1 (no)
CR (1) CR9746A (no)
EC (1) ECSP088214A (no)
GT (1) GT200600383A (no)
IL (2) IL189648A (no)
MX (1) MX2008002484A (no)
NO (1) NO20080991L (no)
PE (1) PE20070425A1 (no)
RU (1) RU2417084C2 (no)
SV (1) SV2008002825A (no)
TW (1) TW200738281A (no)
WO (1) WO2007024961A2 (no)
ZA (1) ZA200801742B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050227966A1 (en) * 2004-04-08 2005-10-13 Wyeth Bazedoxifene acetate formulations
BRPI0615341A2 (pt) * 2005-08-24 2011-05-17 Wyeth Corp composições farmacêuticas contendo acetato de bazedoxifeno, processo para preparação destas e comprimido ou cápsula contendo a referida composição
NZ572106A (en) * 2006-03-31 2010-12-24 Rubicon Res Private Ltd Directly compressible composite for orally disintegrating tablets
WO2008079342A2 (en) * 2006-12-21 2008-07-03 Mallinckrodt Inc. Composition of and method for preparing orally disintegrating tablets
WO2009102771A1 (en) * 2008-02-11 2009-08-20 Wyeth Methods of converting polymorphic form b of bazedoxifene acetate to polymorphic form a of bazedoxifene acetate
ITMI20091109A1 (it) 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
MY163074A (en) * 2010-11-30 2017-08-15 Wista Lab Ltd Formulations comprising methylthioninium chloride
EP2471770A1 (en) * 2010-12-28 2012-07-04 Sandoz Ag Method of preparing polymorphic pure form A of bazedoxifene acetate
WO2013182170A1 (en) 2012-06-07 2013-12-12 Zentiva, K. S. Enhancement of dissolution rate from pharmaceutical composition comprising bazedoxifene acetate
WO2013182169A1 (en) 2012-06-07 2013-12-12 Zentiva, K. S. Process of preparation of an antioxidant-free polymorphically and chemically stable formulation of bazedoxifene acetate
CN103877581B (zh) * 2014-03-24 2016-03-02 江苏知原药业有限公司 一种性能优异的乙酸巴多昔芬缓释制剂
WO2018182205A1 (ko) * 2017-03-30 2018-10-04 한미약품 주식회사 바제독시펜 아세테이트를 함유하는 안정화된 약제학적 조성물
KR101940569B1 (ko) * 2017-05-24 2019-01-21 아주대학교산학협력단 바제독시펜 또는 이의 약학적으로 허용가능한 염을 포함하는 약학 조성물
CN112076163B (zh) * 2019-06-14 2023-06-20 四川科伦药物研究院有限公司 一种醋酸巴多昔芬片的药物组合物及其制备方法
CN111004165A (zh) * 2019-12-03 2020-04-14 南京正济医药研究有限公司 一种醋酸巴多昔芬晶型a的制备方法
CN112754999A (zh) * 2021-01-23 2021-05-07 郑州泰丰制药有限公司 一种醋酸巴多昔芬组合物及醋酸巴多昔芬薄膜衣片制备方法
CN113368075A (zh) * 2021-06-29 2021-09-10 郑州泰丰制药有限公司 一种醋酸巴多昔芬片及其制备方法
JP2024532402A (ja) * 2021-08-23 2024-09-05 オキシジェン バイオテック エルエルシー Ｃｏｖｉｄ－１９の治療

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686094A (en) * 1991-04-01 1997-11-11 Theratech, Inc. Controlled release formulations for the treatment of xerostomia
CZ289133B6 (cs) * 1995-06-22 2001-11-14 Akzo Nobel N. V. Výlisek, tablety nebo granule a způsob jejich výroby
US5998402A (en) 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
MXPA02007957A (es) 2000-02-17 2002-11-29 Amgen Inc Inhibidores de cinasas.
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
EP1531807A4 (en) * 2002-06-13 2007-10-31 Wyeth Corp Bazedoxifene TREATMENT SCHEMES
AU2005206137A1 (en) * 2004-01-13 2005-08-04 Wyeth Treatment of aromatase inhibitor therapy-related osteoporosis
UA85703C2 (en) * 2004-04-07 2009-02-25 Уайет Crystalline polymorph of bazedoxifene acetate
US7683051B2 (en) 2004-04-07 2010-03-23 Wyeth Crystalline polymorph of bazedoxifene acetate
JP2007532548A (ja) 2004-04-07 2007-11-15 ワイス バゼドキシフェンアセテートの結晶質多形体
US20050227966A1 (en) * 2004-04-08 2005-10-13 Wyeth Bazedoxifene acetate formulations
BRPI0615341A2 (pt) * 2005-08-24 2011-05-17 Wyeth Corp composições farmacêuticas contendo acetato de bazedoxifeno, processo para preparação destas e comprimido ou cápsula contendo a referida composição

Also Published As

Publication number Publication date
TW200738281A (en) 2007-10-16
CA2620174A1 (en) 2007-03-01
IL189648A0 (en) 2008-08-07
RU2417084C2 (ru) 2011-04-27
JP2009506053A (ja) 2009-02-12
JP2013209419A (ja) 2013-10-10
ZA200801742B (en) 2010-10-27
IL189648A (en) 2014-07-31
IL233392A (en) 2017-02-28
BRPI0615341A2 (pt) 2011-05-17
PE20070425A1 (es) 2007-07-02
AR056471A1 (es) 2007-10-10
MX2008002484A (es) 2008-04-07
AU2006283121A1 (en) 2007-03-01
KR101584674B1 (ko) 2016-01-13
GT200600383A (es) 2007-03-29
CN101304731B (zh) 2012-06-20
WO2007024961A3 (en) 2007-06-28
US20070048374A1 (en) 2007-03-01
US7771744B2 (en) 2010-08-10
ECSP088214A (es) 2008-03-26
RU2008107580A (ru) 2009-09-27
SV2008002825A (es) 2008-06-30
KR20080043853A (ko) 2008-05-19
IL233392A0 (en) 2014-08-31
EP1919456A2 (en) 2008-05-14
CR9746A (es) 2008-08-21
KR20140088917A (ko) 2014-07-11
CN101304731A (zh) 2008-11-12
WO2007024961A2 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
NO20080991L (no) Bazedoksifen acetat formuleringer
NO20083147L (no) Anti-OX40L-antistoffer og fremgangsmater for anvendelse av disse
DK1902037T3 (da) 2,4-diamino-pyrimidiner som auroainhibitorer
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
EA200701918A1 (ru) Белок липокалин
EA200900781A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды
EP1919302B8 (en) Food comprising silicon
NO20081160L (no) Benzimidazoltiofen forbindelser
HRP20080564T3 (en) Dihydrotetrabenazines and pharmaceutical compositions containing them
HUE042561T2 (hu) Anti-IL-23-ellenanyagok, készítmények, eljárások és alkalmazások
TW200730490A (en) Photoactive compounds
CY1112511T1 (el) Κρυσταλλικη στερεα βαση ρασαγιλινης (rasagiline)
DK3348624T3 (da) Sammensætninger, der omfatter hfc-1234yf
WO2007130697A3 (en) Anti-ephb4 antibodies and methods using same
BRPI0813341A2 (pt) " uso de compostos, composições curáveis, e, uso de composições curáveis ".
NO20065046L (no) Krystallinsk polymorf av bazedoksifenacetat
ATE503759T1 (de) 7-ä2-ä4-(6-fluor-3-methyl-1,2-benzisoxazol-5-yl - 1-piperazinylüethylü-2-(1-propinyl)-7h-pyrazolo
DE502006005053D1 (de) Spritzbare akustikmassen
NO20083593L (no) Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse
EA200800713A1 (ru) Аморфные твёрдые дисперсии
HK1133642A1 (en) Azaadamantane ester and carbamate derivatives and methods of use thereof
FR2923834B1 (fr) Nouvelles compositions polysicocyanates hydrodispersibles.
MX2009010176A (es) Derivados de aza-adamantano 4-substituidos y metodos de uso de los mismos.
EA200600404A1 (ru) Пероральные препаративные формы кладрибина
WO2007060645A3 (en) Stable odorant systems

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application